[{"id":"92f8d52f-8230-4bcf-832a-25726a2e7d8a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03190941","created_at":"2021-01-18T15:44:01.911Z","updated_at":"2024-07-02T16:34:38.067Z","phase":"Phase 1/2","brief_title":"Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients","source_id_and_acronym":"NCT03190941","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • ALK • NRAS • HRAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • KRAS G12V • HRAS mutation • KRAS G12 • NRAS G12 • HLA-A*11 • NRAS G12V","tags":["KRAS • ALK • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • KRAS G12V • HRAS mutation • KRAS G12 • NRAS G12 • HLA-A*11 • NRAS G12V"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 09/21/2017","start_date":" 09/21/2017","primary_txt":" Primary completion: 06/29/2027","primary_completion_date":" 06/29/2027","study_txt":" Completion: 06/29/2028","study_completion_date":" 06/29/2028","last_update_posted":"2024-06-05"},{"id":"bce05c4f-6c6a-4884-8079-4fd16c00542d","acronym":"KISIMA-02","url":"https://clinicaltrials.gov/study/NCT05846516","created_at":"2023-05-06T14:04:12.085Z","updated_at":"2024-07-02T16:34:59.526Z","phase":"Phase 1","brief_title":"A Study to Evaluate ATP150/ATP152, VSV-GP154 and Ezabenlimab in Patients With KRAS G12D/G12V Mutated PDAC (KISIMA-02)","source_id_and_acronym":"NCT05846516 - KISIMA-02","lead_sponsor":"Amal Therapeutics","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12D • KRAS G12V • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12D • KRAS G12V • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ezabenlimab (BI 754091) • ATP150 • ATP152 • Kisima (ATP128) • VSV-GP154"],"overall_status":"Recruiting","enrollment":" Enrollment 85","initiation":"Initiation: 03/13/2023","start_date":" 03/13/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2024-06-03"},{"id":"edef415f-bd84-49a1-9a8c-360704fed600","acronym":"","url":"https://clinicaltrials.gov/study/NCT05786924","created_at":"2023-03-28T14:04:59.609Z","updated_at":"2024-07-02T16:35:02.207Z","phase":"Phase 1","brief_title":"A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers","source_id_and_acronym":"NCT05786924","lead_sponsor":"Black Diamond Therapeutics, Inc.","biomarkers":" KRAS • BRAF • NRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • BRAF mutation • NRAS mutation • KRAS G12D • KRAS G12V • KRAS G12 • NRAS G12D","tags":["KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • BRAF mutation • NRAS mutation • KRAS G12D • KRAS G12V • KRAS G12 • NRAS G12D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e S241656"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 04/18/2023","start_date":" 04/18/2023","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-05-21"},{"id":"2b7c4292-573a-4f4f-aeb9-0287544f452d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03592888","created_at":"2021-01-18T17:39:37.238Z","updated_at":"2024-07-02T16:35:05.451Z","phase":"Phase 1","brief_title":"DC Vaccine in Pancreatic Cancer","source_id_and_acronym":"NCT03592888","lead_sponsor":"University of Pennsylvania","biomarkers":" KRAS • HLA-A","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12R • HLA-A*03 • KRAS G12 • HLA-A*02 • HLA-A*11","tags":["KRAS • HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12R • HLA-A*03 • KRAS G12 • HLA-A*02 • HLA-A*11"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 11/20/2018","start_date":" 11/20/2018","primary_txt":" Primary completion: 02/12/2024","primary_completion_date":" 02/12/2024","study_txt":" Completion: 02/12/2024","study_completion_date":" 02/12/2024","last_update_posted":"2024-05-07"},{"id":"d557545c-a8fc-4f7f-9d63-eb284cbe8b60","acronym":"AMPLIFY-7P","url":"https://clinicaltrials.gov/study/NCT05726864","created_at":"2023-02-14T18:02:24.073Z","updated_at":"2024-07-02T16:35:05.951Z","phase":"Phase 1/2","brief_title":"A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors","source_id_and_acronym":"NCT05726864 - AMPLIFY-7P","lead_sponsor":"Elicio Therapeutics","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • NRAS mutation • KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12 • KRAS G12S • NRAS G12D • NRAS G12 • NRAS G13 • NRAS G12S • NRAS G12V","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • NRAS mutation • KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12 • KRAS G12S • NRAS G12D • NRAS G12 • NRAS G13 • NRAS G12S • NRAS G12V"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ELI-002 7P"],"overall_status":"Recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 04/14/2023","start_date":" 04/14/2023","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-05-03"},{"id":"59c4433e-178c-41e8-bb65-1d9a0a1d95a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05631899","created_at":"2022-11-30T17:57:34.718Z","updated_at":"2024-07-02T16:35:20.773Z","phase":"Phase 1","brief_title":"CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors","source_id_and_acronym":"NCT05631899","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" KRAS","pipe":" | ","alterations":" PD-L1 expression • KRAS mutation • MSI-H/dMMR • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KRAS mutation • MSI-H/dMMR • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • albumin-bound paclitaxel • cyclophosphamide • KRAS-EphA-2-CAR-DC"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 04/03/2023","start_date":" 04/03/2023","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2024-02-06"},{"id":"ccf0a3d0-2d12-4172-9a35-f6327f190184","acronym":"","url":"https://clinicaltrials.gov/study/NCT05254184","created_at":"2022-02-24T14:52:57.088Z","updated_at":"2024-07-02T16:35:22.368Z","phase":"Phase 1","brief_title":"KRAS-Targeted Vaccine With Nivolumab and Ipilimumab for Patients With NSCLC","source_id_and_acronym":"NCT05254184","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G13D • KRAS G12R • KRAS G12A • KRAS G12 • KRAS G13","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G13D • KRAS G12R • KRAS G12A • KRAS G12 • KRAS G13"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2024-01-24"},{"id":"a908832d-a81e-40f3-9e03-9eb6223d1ad7","acronym":"RAMP-202","url":"https://clinicaltrials.gov/study/NCT04620330","created_at":"2021-01-19T20:34:21.364Z","updated_at":"2024-07-02T16:35:23.520Z","phase":"Phase 2","brief_title":"A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04620330 - RAMP-202","lead_sponsor":"Verastem, Inc.","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • KRAS G12V • KRAS G12","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • KRAS G12V • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avmapki (avutometinib) • Fakzynja (defactinib)"],"overall_status":"Completed","enrollment":" Enrollment 90","initiation":"Initiation: 12/31/2020","start_date":" 12/31/2020","primary_txt":" Primary completion: 08/29/2023","primary_completion_date":" 08/29/2023","study_txt":" Completion: 12/12/2023","study_completion_date":" 12/12/2023","last_update_posted":"2024-01-12"},{"id":"5cfcbe7d-4d03-4117-95be-9b8d7199f4ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT04146298","created_at":"2021-01-18T20:14:11.889Z","updated_at":"2024-07-02T16:35:38.229Z","phase":"Phase 1/2","brief_title":"Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer","source_id_and_acronym":"NCT04146298","lead_sponsor":"Changhai Hospital","biomarkers":" KRAS • NRAS • HRAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • KRAS G12V • HRAS mutation • KRAS G12 • NRAS G12 • HLA-A*11 • NRAS G12V • KRAS expression","tags":["KRAS • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • KRAS G12V • HRAS mutation • KRAS G12 • NRAS G12 • HLA-A*11 • NRAS G12V • KRAS expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/21/2021","start_date":" 10/21/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2023-09-01"},{"id":"39082f6c-8d92-4c46-9e0c-a8aeaf83e623","acronym":"","url":"https://clinicaltrials.gov/study/NCT05173805","created_at":"2021-12-30T14:55:47.563Z","updated_at":"2024-07-02T16:35:42.768Z","phase":"Phase 1/2","brief_title":"Phase I Clinical Study of YL-15293 in Patients With Advanced Solid Tumor With KRAS Mutation","source_id_and_acronym":"NCT05173805","lead_sponsor":"Shanghai YingLi Pharmaceutical Co. Ltd.","biomarkers":" PD-L1 • KRAS • MSI • PD-1","pipe":" | ","alterations":" KRAS mutation • MSI-H/dMMR • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12","tags":["PD-L1 • KRAS • MSI • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • MSI-H/dMMR • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e YL-15293"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 150","initiation":"Initiation: 01/30/2022","start_date":" 01/30/2022","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2023-07-18"},{"id":"71b5ac1d-448a-4fe7-bdf6-62e302fd6938","acronym":"","url":"https://clinicaltrials.gov/study/NCT05438667","created_at":"2022-06-30T17:02:13.557Z","updated_at":"2024-07-02T16:35:42.685Z","phase":"Phase 1","brief_title":"TCR-T Cell Therapy on Advanced Pancreatic Cancer","source_id_and_acronym":"NCT05438667","lead_sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12D • KRAS G12V • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12D • KRAS G12V • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 06/07/2022","start_date":" 06/07/2022","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 05/30/2026","study_completion_date":" 05/30/2026","last_update_posted":"2023-07-18"},{"id":"2188e1a4-494f-4dad-8033-4ac6b374cbbc","acronym":"FRAME","url":"https://clinicaltrials.gov/study/NCT03875820","created_at":"2021-01-17T17:43:26.582Z","updated_at":"2024-07-02T16:35:43.556Z","phase":"Phase 1","brief_title":"Phase I Trial of Defactinib and VS-6766.","source_id_and_acronym":"NCT03875820 - FRAME","lead_sponsor":"Institute of Cancer Research, United Kingdom","biomarkers":" KRAS • RAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12V • RAS mutation • KRAS G12","tags":["KRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12V • RAS mutation • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avmapki (avutometinib) • Fakzynja (defactinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 87","initiation":"Initiation: 12/12/2017","start_date":" 12/12/2017","primary_txt":" Primary completion: 04/30/2023","primary_completion_date":" 04/30/2023","study_txt":" Completion: 10/31/2023","study_completion_date":" 10/31/2023","last_update_posted":"2023-07-10"},{"id":"41426191-e861-4497-bd26-22264d4bdb1e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05933668","created_at":"2023-07-06T16:10:24.750Z","updated_at":"2024-07-02T16:35:43.789Z","phase":"Phase 1","brief_title":"Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Solid Tumor","source_id_and_acronym":"NCT05933668","lead_sponsor":"Peking University","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS G12V • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS G12V • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • oxaliplatin • YK0901"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 07/01/2023","start_date":" 07/01/2023","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2023-07-06"},{"id":"b2c74ab4-c1bb-4e58-a7dd-cb64d3bac04a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05651269","created_at":"2022-12-15T15:58:36.795Z","updated_at":"2024-07-02T16:35:59.048Z","phase":"Phase 2","brief_title":"Milciclib in Combination With Gemcitabine in Advanced NSCLC","source_id_and_acronym":"NCT05651269","lead_sponsor":"Tiziana Life Sciences LTD","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G13D • KRAS G12A • KRAS G12 • KRAS G12S • KRAS G13","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G13D • KRAS G12A • KRAS G12 • KRAS G12S • KRAS G13"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • milciclib (TZLS-201)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 03/15/2023","start_date":" 03/15/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2022-12-15"},{"id":"fc0527a0-93cb-423f-bc83-608fc7b18373","acronym":"","url":"https://clinicaltrials.gov/study/NCT05202561","created_at":"2022-01-21T13:53:43.259Z","updated_at":"2024-07-02T16:36:14.829Z","phase":"Phase 1","brief_title":"A Study of RNA Tumor Vaccine in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05202561","lead_sponsor":"First Affiliated Hospital Bengbu Medical College","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12D • KRAS G12V • HLA-A*11","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12D • KRAS G12V • HLA-A*11"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 03/10/2022","start_date":" 03/10/2022","primary_txt":" Primary completion: 01/19/2023","primary_completion_date":" 01/19/2023","study_txt":" Completion: 01/19/2024","study_completion_date":" 01/19/2024","last_update_posted":"2022-03-23"},{"id":"3e733719-38e5-4a1a-84cc-2fa12560b62b","acronym":"NVALT22","url":"https://clinicaltrials.gov/study/NCT02743923","created_at":"2021-01-18T13:26:33.640Z","updated_at":"2024-07-02T16:36:19.295Z","phase":"Phase 3","brief_title":"Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer","source_id_and_acronym":"NCT02743923 - NVALT22","lead_sponsor":"The Netherlands Cancer Institute","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12D • KRAS G12V • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12D • KRAS G12V • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel • pemetrexed"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 203","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 09/19/2021","primary_completion_date":" 09/19/2021","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2021-12-21"},{"id":"8eff224f-dd6c-4358-93e8-9182bfd305b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT00837135","created_at":"2021-01-18T03:11:13.477Z","updated_at":"2024-07-02T16:37:29.739Z","phase":"Phase 1","brief_title":"GI-4000 With Adoptive Transfer in Pancreatic Cancer","source_id_and_acronym":"NCT00837135","lead_sponsor":"University of Pennsylvania","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12 • KRAS Q61L • KRAS expression","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12 • KRAS Q61L • KRAS expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GI-4000"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/01/2008","start_date":" 01/01/2008","primary_txt":" Primary completion: 10/01/2009","primary_completion_date":" 10/01/2009","study_txt":" Completion: 10/01/2009","study_completion_date":" 10/01/2009","last_update_posted":"2016-08-17"}]